Article Image

IPFS News Link • Vaccines and Vaccinations

McCullough: Pandemic Won't End Until Mass Vaccination Stops

• By Peter A. McCullough, M.D., MPH

A principle of infectious diseases is "antimicrobial stewardship" which involves choosing the right antibiotic for the right patient and never over-prescribing or blanket-covering patients who don't need treatment.

Another principle is "narrowing the spectrum" of a drug once the organism is identified by culture or other methods.

These fundamental approaches to the use of antibiotics work to limit the problem of bacterial resistance and the development of "superbugs."

Every year hospitals each produce their antibiogram or report of their common infections encountered and what antibiotics either are effective (organism is sensitive) or ineffective (organism is resistant).

In the SARS-CoV-2 pandemic, these principles have been applied to the use of monoclonal antibodies and the process explains why various EUA products (e.g., bamlanivimab) were pulled from the market when they were understood to be no longer effective at neutralizing SARS-CoV-2.

This entire thought process has been thrown out the window for COVID-19 vaccines. For 18 months the ancestral strain Wuhan Institute of Virology spike protein was the featured antigen for Pfizer, Moderna, Janssen, AstraZeneca and Novavax vaccines.

Within a few months, there was mounting evidence that SARS-CoV-2 easily mutated to escape the reach of antibodies generated by the vaccines which would apply to serious invasive illness (IgG and IgM).

Because the COVID-19 vaccines have never been demonstrated to neutralize SARS-CoV-2 in the nasopharynx, the only theoretical benefit would be for systemic disease.